Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
Condition(s):MelanomaLast Updated:September 6, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):MelanomaLast Updated:September 6, 2022Recruiting
Condition(s):Clinical Features and OutcomeLast Updated:July 16, 2021Recruiting
Condition(s):Nodding Syndrome; Epilepsy; Onchocerciasis; Cognitive ImpairmentLast Updated:August 31, 2018Unknown status
Condition(s):Combined Central and Peripheral Demyelination DiseaseLast Updated:December 16, 2020Unknown status
Condition(s):Bone and Soft Tissue Tumors; Clinical FeaturesLast Updated:September 1, 2023Recruiting
Condition(s):UveitisLast Updated:August 24, 2018Completed
Condition(s):Autoimmune Liver Disease, COVID-19Last Updated:October 25, 2023Active, not recruiting
Condition(s):SARS-CoV2Last Updated:May 20, 2021Completed
Condition(s):StrokeLast Updated:August 5, 2022Completed
Condition(s):Aortic Dissection; Pregnancy RelatedLast Updated:September 27, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.